Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese pharmaceutical firm Astellas Pharma and MSD K.K., a subsidiary of Merck, have introduced the selective SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor Suglat tablets 25mg and 50mg in Japan for the treatment of type 2 diabetes.
Subscribe to our email newsletter
Suglat Tablets are discovered through a research collaboration and is being jointly developed by Astellas and Kotobuki Pharmaceutical (Kotobuki).
The company said that SGLTs are membrane proteins that exist on the cell surface and transfer glucose into cells.
SGLT2 is one subtype of SGLTs and plays a major role in the reuptake of glucose in the proximal tubule of the kidneys.
Suglat tablets, which is the first SGLT2 inhibitor approved as a treatment for type 2 diabetes in Japan, reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2.
The Japanese firm will manufacture and sell Suglat tablets and co-promote it with Kotobuki and MSD.